Entering text into the input field will update the search result below

Ocular Therapeutix (OCUL) CEO Antony Mattessich on Q1 2020 Results - Earnings Call Transcript

May 08, 2020 2:11 PM ETOcular Therapeutix, Inc. (OCUL)
SA Transcripts profile picture
SA Transcripts

Ocular Therapeutix (NASDAQ:OCUL) Q1 2020 Results Conference Call May 8, 2020 8:30 AM ET

Company Participants

Donald Notman - CFO

Antony Mattessich - President and CEO

Dr. Michael Goldstein - Chief Medical Officer

Conference Call Participants

Joe Catanzaro - Piper Sandler

Stacy Ku - Cowen & Co.

Jonathan Wolleben - JMP Securities

Boobalan Pachaiyappan - H.C. Wainwright


Ladies and gentlemen, thank you for standing by and welcome to the First Quarter 2020 Ocular Therapeutix Earnings Conference Call. At this time, all participant lines are in listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions]

I'd now like to hand the conference over to your speaker today, Mr. Donald Notman, Chief Financial Officer. Please go ahead, sir.

Donald Notman

Thank you, operator. Good morning, everyone, and thank you for joining us on our first quarter 2020 financial results and business update conference call.

This morning, before the opening, we issued a press release providing an update on the Company’s product development programs and details of the Company’s financial results for the quarter ended March 31, 2020. The press release can be accessed on the Investors portion of our website at investors.ocutx.com.

Leading the call today will be Antony Mattessich, our President and Chief Executive Officer, who will provide a summary of our corporate development and an update on the DEXTENZA commercial launch. Also speaking on the call today will be Dr. Michael Goldstein, our Chief Medical Officer, who will give an update on our clinical developments and pipeline. Following Michael’s remarks, I will provide an overview of the financial highlights for the quarter, before turning the call back over to Antony for a summary and questions.

As a reminder, on today’s call, we will be making forward-looking statements regarding our regulatory and product development plans as well

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.